Nello Mainolfi - 12 May 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
12 May 2021
Net transactions value
-$395,527
Form type
4
Filing time
14 May 2021, 17:20:36 UTC
Next filing
19 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $17,150 +8,245 +2.1% $2.08* 405,444 12 May 2021 Direct
transaction KYMR Common Stock Sale $412,677 -8,245 -2% $50.05 397,199 12 May 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -8,245 -3.7% $0.000000 216,480 12 May 2021 Common Stock 8,245 $2.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.